A Pivotal, Open-label Trial Assessing the Safety and Efficacy of the 0.5 mg Dutasteride and 0.4 mg Tamsulosin Combination Once Daily for Six Months in Patients With Benign Prostatic Hyperplasia

Trial Profile

A Pivotal, Open-label Trial Assessing the Safety and Efficacy of the 0.5 mg Dutasteride and 0.4 mg Tamsulosin Combination Once Daily for Six Months in Patients With Benign Prostatic Hyperplasia

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 23 Dec 2015

At a glance

  • Drugs Dutasteride/tamsulosin (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FDC114785
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Dec 2015 Trial focus has been changed from AR to TU+AR and endpoints has been added related to TU as reported by ClinicalTrials.gov record.
    • 21 Jul 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top